In Brief: Sanofi
This article was originally published in The Gray Sheet
Executive Summary
Sanofi: Launches its Access CK-MB Assay, a two-site immunoenzymatic (sandwich) test that "utilizes paramagnetic particle, chemiluminescent technology to determine CK-MB levels in human serum or plasma EDTA." The assay will be sold in packages of 100 determinations. Each package will carry a list price of $650, the company says. "The development and commercialization of our Access CK-MB assay represents Sanofi Diagnostic Pasteur, Inc.'s commitment to providing a full cardiac menu on the Access System," the company says, noting that it plans to launch Access assays for Myoglobin and Troponin I in 1996...